Onset of action of antisecretory drugs: Beneficial effects of a rapid increase in intragastric pH in acid reflux disease

Scandinavian Journal of Gastroenterology, Supplement

Volumn 33, Issue 34, 1999, Pages 3-8

  Pipkin, G A ^a   Mills, J G ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Acid reflux disease; Effervescent tablet; Heartburn; Intragastric pH; Ranitidine; Symptom relief

Indexed keywords

BICARBONATE; CIMETIDINE; CITRATE SODIUM; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR;

ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; EFFERVESCENT TABLET; HEARTBURN; HUMAN; PEPTIC ULCER; PHARMACODYNAMICS; PRIORITY JOURNAL; STOMACH PH; DRUG EFFECT; GASTROESOPHAGEAL REFLUX; METABOLISM; PH; REVIEW; SECRETION; STOMACH; STOMACH ACID; STOMACH MUCOSA; TREATMENT OUTCOME;

GASTRIC ACID; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; RANITIDINE; STOMACH; TREATMENT OUTCOME;

EID: 0032855471     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Nebel TO, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Dig Dis 1976;21:953-6.
2. Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of oesophageal disorders. Scand J Gastroenterol 1991;26:73-81.
3. Jones RH, Johnson CD. Reflux symptoms in the general population. Hellenic J Gastroenterol 1992;5 Suppl:142.
4. Jones RH, Lydeard SE, Hobbs DFR, et al. Dyspepsia in England and Scotland. Gut 1990;31:401-5.
5. Johnsson F, Joelsson B, Grundmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987;22:714-8.
6. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8.
7. Jones RH, Hungin APS, Philips J, Mills JG. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995;1:149-54.
8. Savary M, Miller G. The oesophagus. In: Savary M, Miller S, editors. Handbook and atlas of endoscopy. Solothum, Switzerland: Verlag Gassman AG, 1978. p. 119-205.
9. Johnasson KE, Ask P, Boeryd B, Fransson S-G, Tibbling L. Oesophagitis, signs of reflux and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1985;21:837-47.
10. Chiba N, DeGara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in Grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
11. Lambert R. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997;11:651-62.
12. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9 Suppl 1:3-7.
13. Sontag SJ. Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:293-312.
14. Ching C-K, Lam S-K. Antacids. Indications and limitations. Drugs 1994;47:305-17.
15. Marks IN, Schassmann A, Halter F, Lam S-K, Weberg R, Bianchi Porro G, et al. Antacid therapy today. Eur J Gastroenterol Hepatol 1992;4:977-83.
16. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983;78:257-60.
17. Brunton LL. Agents for control of gastric acidity and treatment of peptic ulcers. In: Hardman JG, Limbird LE, Moliniff PB, Rudden RW, Gilman AG, editors. Goodman & Gilman's The pharmacological basis of therapeutics. Ninth edition. New York: McGraw-Hill,. p. 910-3.
18. Weatherall DJ, Ledingham JCG, Warrell DA, editors. Oxford textbook of medicine. Second edition. Oxford: Oxford Medical Communications; 12:71-2.
19. Devis G, De Rop H, Du Ville L, Van Avermaet S, Reynaert R, Micholte Y. Rapid absorption and high plasma concentrations with the ranitidine effervescent formulation results in a very quick onset of action on the intragastric pH. Scand J Gastroenterol 1993;28 Suppl 197:70.
20. Watson RGP, Johnston BT, Tham TCK, Kersey K. Effervescent and standard formulations of ranitidine - a comparison of their pharmacokinetics and pharmacology. Aliment Pharmacol Ther 1996;10:913-8.
21. Smout AJPM, Jonkman JHG, Peeters PAM, De Bruin H. Effect of an evening dose of regular and effervescent formulations of ranitidine or cimetidine on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 1995;9:51-6.
22. Hedenstrom H, Alm C, Kraft M, Grahnen A. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 1997;11:1137-41.
23. Loser Chr, Burlage M, Folsch UR. Influence of ranitidine and famotidine on the intragastric pH-profile in healthy volunteers. Randomised cross-over study of ranitidine effervescent tablets (300 mg) versus famotidine film coated tablets (40 mg). Arzneim Forsch Drug Res 1994;44:626-9.
24. Arnestad JS, Kleveland PM, Waldum HL. In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment Pharmacol Ther 1997;11:355-8.
25. Elm M, Hellke P, Andrén K, Dahl G, Nyth A-L, the Study Group. Time to relief of episodic symptoms of gastrooesophageal reflux disease. A crossover comparison of single doses of the effervescent and standard formulations of ranitidine. Scand J Gastroenterol 1998;33:900-4.
26. Engzelius JM, Sohaug JH, Knapstad LJ, Kjaergaard P. Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1997;32:513-8.